Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 01, 2018 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Report Second Quarter 2018 Financial Results on August 8, 2018

Axsome to host conference call and webcast on Wednesday, August 8, 2018 at 8:00 AM Eastern Time NEW YORK, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
July 17, 2018 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces AXS-05 Presentation at the 2018 Alzheimer’s Association International Conference

NEW YORK, July 17, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
June 05, 2018 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Initiates Phase 2 Trial of AXS-05 in Major Depressive Disorder

First patient enrolled in the ASCEND study Trials in two mood disorders now underway with AXS-05 NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a...
May 29, 2018 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Present Data on AXS-05 at the 2018 American Society of Clinical Psychopharmacology Annual Meeting

NEW YORK, May 29, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system...
May 22, 2018 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Present at the 2018 BIO International Convention

NEW YORK, May 22, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system...
May 08, 2018 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update

NEW YORK, May 08, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system...
May 03, 2018 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces AXS-05 Poster Presentation at the 2018 Annual Meeting of the American Psychiatric Association

NEW YORK, May 03, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system...
May 01, 2018 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018

Axsome to host conference call and webcast on Tuesday, May 8, 2018 at 8:00 AM Eastern Time NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage...
April 26, 2018 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces Positive Outcome of Interim Analysis of STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression

Independent Data Monitoring Committee recommends trial continuation Second interim analysis anticipated second half of 2018 for efficacy NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- Axsome...
April 24, 2018 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine Dependence

NEW YORK, April 24, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...